Dendreon to Host Conference Call on August 8 to Announce Second Quarter
-- Company Announces Webcast Presentations at Upcoming Conference --
Canaccord Genuity Global Growth Conference 2013
SEATTLE -- July 15, 2013
July 15, 2013-- Dendreon Corporation (Nasdaq:DNDN) today announced that
management will host a conference call on Thursday, August 8, 2013, at 4:30
p.m. EDT to review second quarter financial results.
Access to the discussion may be obtained as follows:
Time: 4:30 p.m. EDT / 1:30 p.m. PDT
Date: August 8, 2013
Dial-in: 1-877-548-9590 (domestic) or +1-720-545-0037 (international);
conference pass code: 18807239
Webcast: www.dendreon.com (homepage and investor relations section)
A recorded rebroadcast will be available for interested parties unable to
participate in the live conference call by dialing 1-800-585-8367 or
+1-404-537-3406 for international callers; the conference ID number is
18807239. The replay will be available from 7:30 p.m. EDT on Thursday, August
8, until 11:59 p.m. EDT on Wednesday, August 14. In addition, the webcast will
be archived for on-demand listening for 90 days at www.dendreon.com.
Dendreon Corporation also announced that management will present at the
*Canaccord Genuity 33rd Annual Growth Conference in Boston, MA, on August
14 at 9:00 a.m. EDT
The presentation will be audio webcast live and available for replay from
Dendreon's website, www.dendreon.com. If you are unable to listen to the live
webcast, it will be archived on the site following the presentation. To access
the replay, go to the Investor Relations section of the website.
Dendreon Corporation is a biotechnology company whose mission is to target
cancer and transform lives through the discovery, development,
commercialization and manufacturing of novel therapeutics. The Company applies
its expertise in antigen identification, engineering and cell processing to
produce active cellular immunotherapy (ACI) product candidates designed to
stimulate an immune response in a variety of tumor types. Dendreon's first
product, PROVENGE^® (sipuleucel-T), was approved by the U.S. Food and Drug
Administration (FDA) in April 2010. Dendreon is exploring the application of
additional ACI product candidates and small molecules for the potential
treatment of a variety of cancers. The Company is headquartered in Seattle,
Washington and is traded on the NASDAQ Global Market under the symbol DNDN.
For more information about the Company and its programs, visit
Lindsay Rocco, 862-596-1304
Nicole Soley, 206-455-2220
Press spacebar to pause and continue. Press esc to stop.